person · Reporting owner

FOUSE JACQUALYN A

Disclosed activity across 5 companies

Tapewire entity: 35960
SEC CIK: 0001405288

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499	Director	June 18, 2026	June 23, 2026
CELGENE CORP /DE/CELG · Entity 15781	Director · see remarks	February 14, 2017	February 16, 2017
DICK'S SPORTING GOODS, INC.DKS · Entity 556	Director	March 22, 2020	March 24, 2020
INCYTE CORPINCY · Entity 3182	Director	June 08, 2026	June 10, 2026
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	Director	June 17, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	154,156	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 154,156
Restricted stock unitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Restricted stock unitsSEC Table II · derivative / convertible security	Direct	2,927	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18	Direct	14,950	Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

CELGENE CORP /DE/

Report date February 14, 2017 · Filed February 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	16,322	Reported balance After 2017-02-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-02-14 · Grant · Acquired 16,322 · Balance 16,322 F1: Each share of phantom stock represents a right to receive one share of common stock. F3: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan. F2: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of phantom stock represents a right to receive one share of common stock.

F2: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation.

F3: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan.

DICK'S SPORTING GOODS, INC.

Report date March 22, 2020 · Filed March 24, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	55,288	Reported balance After 2020-03-22 transaction · row 1 1 source row Row 1 · 2020-03-22 · Grant · Acquired 9,518 · Balance 55,288 F1: Shares of time-based restricted stock, subject to vesting.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of time-based restricted stock, subject to vesting.

INCYTE CORP

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,968	Reported balance After 2026-06-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 20,968 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07	Direct	6,111	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

MADRIGAL PHARMACEUTICALS, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,551	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 454 · Balance 1,551 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17	Direct	766	Reported balance After 2026-06-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 31, 2018 Filed Jun 4, 2018 20:19 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	1,400	$0.00	$0.00	Disclosure SEC source: 0001209191-18-035052 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
May 31, 2018 Filed Jun 4, 2018 20:19 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	5,700	$0.00 Strike: $93.50	$0.00	Disclosure SEC source: 0001209191-18-035052 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document
May 01, 2018 Filed May 3, 2018 21:33 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $60.85	$0.00	Disclosure SEC source: 0001209191-18-027762 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document
April 03, 2018 Filed Apr 5, 2018 20:33 UTC	DICK'S SPORTING GOODS, INC. DKS · Entity 556	GrantCommon Stock, par value $0.01 per share	4,732	$0.00	$0.00	Disclosure SEC source: 0001089063-18-000048 · wf-form4_152296037022871.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,589 F1 · shares: Shares of time-based restricted stock, subject to vesting. Read SEC document
March 29, 2018 Filed Apr 3, 2018 20:30 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	150	$83.33	$12,499.50	Disclosure SEC source: 0001209191-18-022973 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document
December 03, 2017 Filed Dec 5, 2017 21:15 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock option (right to buy) · Derivative	16,000	$0.00 Strike: $61.17	$0.00	Disclosure SEC source: 0001209191-17-063895 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common stock · 16,000 shares Expires 2027-12-02 F1 · derivative.exercise_date: This option was granted on December 3, 2017. The shares underlying this option vest as to 25% of the underlying shares on December 2, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document
November 14, 2017 Filed Nov 16, 2017 21:27 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	8,750	$0.00 Strike: $105.12	$0.00	Disclosure SEC source: 0001209191-17-061185 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2027-11-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document
November 14, 2017 Filed Nov 16, 2017 21:27 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $105.12	$0.00	Disclosure SEC source: 0001209191-17-061185 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-13 F1 · derivative.exercise_date: Beginning November 14, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on November 14, 2018 and the remainder vesting monthly over three years. Read SEC document
June 20, 2017 Filed Jun 22, 2017 20:45 UTC	DICK'S SPORTING GOODS, INC. DKS · Entity 556	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $27.13	$0.00	Disclosure SEC source: 0001089063-17-000064 · wf-form4_149816429578499.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 20,000 shares Expires 2017-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option grant representing the right to purchase 20,000 shares of common stock vested in four equal installments beginning on September 15, 2011. Read SEC document
June 20, 2017 Filed Jun 22, 2017 20:45 UTC	DICK'S SPORTING GOODS, INC. DKS · Entity 556	Exercise / conversionCommon Stock, par value $0.01 per share	20,000	$27.13	$542,600.00	Disclosure SEC source: 0001089063-17-000064 · wf-form4_149816429578499.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 03, 2017 Filed Apr 5, 2017 22:43 UTC	DICK'S SPORTING GOODS, INC. DKS · Entity 556	GrantCommon Stock, par value $0.01 per share	3,261	$0.00	$0.00	Disclosure SEC source: 0001089063-17-000032 · wf-form4_149143221167213.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,857 F1 · shares: Shares of time-based restricted stock, subject to vesting. Read SEC document
February 14, 2017 Filed Feb 16, 2017 17:14 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantPhantom Stock · Derivative	16,322	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-011571 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,322 Underlying: Common Stock · 16,322 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock represents a right to receive one share of common stock. F3 · price: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan. F2 · derivative.exercise_date: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation. F2 · derivative.expiration_date: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation. Read SEC document
January 30, 2017 Filed Jan 31, 2017 16:21 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	18,543	Not disclosed Strike: $113.18	Not disclosed	Disclosure SEC source: 0001209191-17-006362 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,543 Underlying: Common Stock · 18,543 shares Expires 2027-01-30 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). Read SEC document
December 02, 2016 Filed Dec 6, 2016 16:04 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-16-153643 · doc4.xml · derivative · entry 4 FOUSE JACQUALYN A · CIK 0001405288 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 02, 2016 Filed Dec 6, 2016 16:04 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	2,352	$117.63	$276,665.76	Disclosure SEC source: 0001209191-16-153643 · doc4.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,040 Read SEC document
December 02, 2016 Filed Dec 6, 2016 16:04 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-16-153643 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. Read SEC document
October 31, 2016 Filed Nov 2, 2016 16:13 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	18,543	Not disclosed Strike: $102.18	Not disclosed	Disclosure SEC source: 0001209191-16-147897 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,543 Underlying: Common Stock · 18,543 shares Expires 2026-10-31 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 31, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.